CONCA, VERONICA
 Distribuzione geografica
Continente #
NA - Nord America 310
EU - Europa 294
AS - Asia 119
AF - Africa 46
OC - Oceania 1
Totale 770
Nazione #
US - Stati Uniti d'America 310
IT - Italia 177
SG - Singapore 84
SE - Svezia 52
CI - Costa d'Avorio 34
CN - Cina 15
DE - Germania 15
BG - Bulgaria 13
PL - Polonia 12
GB - Regno Unito 11
HK - Hong Kong 10
SN - Senegal 6
AT - Austria 5
NG - Nigeria 5
FR - Francia 4
IN - India 4
KR - Corea 4
FI - Finlandia 3
AU - Australia 1
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
IL - Israele 1
KH - Cambogia 1
Totale 770
Città #
Chandler 74
Abidjan 34
New York 34
Florence 27
Genoa 18
Los Angeles 16
Singapore 16
Fairfield 15
Lawrence 13
Princeton 13
Sofia 13
Warsaw 12
Ogden 11
Ashburn 10
Bremen 10
London 10
Medford 10
Milan 10
Naples 10
Rome 10
Pisa 9
Dakar 6
Hong Kong 6
Wilmington 6
Lagos 5
Turin 5
Vienna 5
Kent 4
Pistoia 4
San Diego 4
Seoul 4
Shanghai 4
Verona 4
Adria 3
Ann Arbor 3
Coreglia Antelminelli 3
Houston 3
Anzio 2
Boardman 2
Buti 2
Carini 2
Center 2
Civitanova Marche 2
Cologno Monzese 2
Hyderabad 2
Leverkusen 2
Noventa di Piave 2
Osimo 2
Padova 2
Peccioli 2
Salerno 2
San Giuliano Terme 2
San Miniato Basso 2
Tempe 2
Vitry-sur-seine 2
Washington 2
Woodbridge 2
Berlingo 1
Billings 1
Cairo 1
Cascina 1
Castellana Grotte 1
Castiglione Chiavarese 1
Catania 1
Central 1
Città della Pieve 1
Deiva Marina 1
Edinburgh 1
Helsinki 1
Indore 1
Kowloon 1
Lappeenranta 1
Longhena 1
Melbourne 1
Minervino Murge 1
Perugia 1
Phnom Penh 1
Pune 1
Sant Joan Despí 1
Seattle 1
Selargius 1
Spresiano 1
Tel Aviv 1
Torrevecchia Pia 1
Venice 1
Totale 512
Nome #
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 61
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 56
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 48
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 48
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies 45
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study 44
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 44
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study 41
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 41
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 41
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 39
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 37
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers 36
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 29
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 24
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 22
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 21
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 20
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 20
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 20
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 19
Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis 18
null 15
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 14
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 13
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 7
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 5
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 4
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 3
Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials 2
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 2
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study 2
Totale 841
Categoria #
all - tutte 4.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.498


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 10 1 12 10 1 7 13 5 18 34
2022/2023319 23 45 19 19 29 37 10 18 79 1 33 6
2023/2024409 16 29 53 41 30 48 54 13 17 25 44 39
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 841